Ex Schering-Plough Clinical Research EVP Named CMO of PTC Therapeutics

Regular readers will recall that New Merck inherited a $200 million outflow collaboration (for the development and commercialization of the compounds in the Legacy Schering-Plough/PTC Hepatitis C research and development program), back in November of 2009 -- when the bust-up first closed.

Many of the sharper readers will likewise recall the Celgene-Carrie Cox connections (she too is ex-Schering-Plough; Celgene has a $20 million equity investment in PTC Therapeutics -- and is collaborating on an oncology targets discovery program with PTC), but let's not overlook the Warburg Pincus overlaps (see below). In any event, here's a bit of the blurb, from the PR Newswires:

. . . .While at Schering-Plough, Dr. Spiegel was involved in the filing of over thirty New Drug Applications and interacted with regulatory authorities in the U.S. and globally on a regular basis, serving on the executive committees overseeing all research projects and drug licensing activities. Dr. Spiegel joined Schering-Plough in 1983 as Director, Clinical Research, progressing through clinical operations as Vice President of Clinical Research, Senior Vice President of Worldwide Clinical Research and then becoming Chief Medical Officer in 1998. He received his undergraduate degree, cum laude, from Yale University and his medical degree from the University of Pennsylvania. Dr. Spiegel continues to serve on the Board of Directors and Scientific Advisory Committees of a number of companies and is an Advisor at Warburg Pincus. . . .

Obviously, of course, Warburg is where the Ex-CEO of Schering-Plough, one "Fast" Fred Hassan, apparently still hangs his primary hat. . . Cozy. we will report additional intersections, as we uncover them, here. Do stay tuned.

UPDATED: Bob Bertonlini's new place is connected, too: PTC has an exclusive collaboration with Genzyme Corporation (where Bertolini chairs the Audit Committee of the Board of Directors), for the development and commercialization of ataluren (a PTC candidate). PTC will market ataluren in the United States and Canada, while Genzyme will commercialize the product in other regions of the world, we are reliably informed.